β2 microglobulin also known as B2M is a component of MHC class I molecules, MHC class I molecules have α1, α2, and α3 proteins which are present on all nucleated cells (excludes red blood cells).[1][2] In humans, the β2 microglobulin protein[3] is encoded by the B2Mgene.[2][4]
β2 microglobulin lies beside the α3 chain on the cell surface. Unlike α3, β2 has no transmembrane region. Directly above β2 (that is, further away from the cell) lies the α1 chain, which itself is next to the α2.
β2 microglobulin associates not only with the alpha chain of MHC class I molecules, but also with class I-like molecules such as CD1 and Qa.
An additional function is association with the HFE protein, together regulating the expression of hepcidin in the liver which targets the iron transporter ferroportin on the cytoplasmic membrane of enterocytes and macrophages for degradation resulting in increased iron uptake from food and decreased iron release from recycled red blood cells in the MPS (mononuclear phagocyte system) respectively. Loss of this function causes iron excess and hemochromatosis.[citation needed]
Mice models deficient for the β2 microglobulin gene have been engineered. These mice demonstrate that β2 microglobulin is necessary for cell surface expression of MHC class I and stability of the peptide binding groove. In fact, in the absence of β2 microglobulin, very limited amounts of MHC class I (classical and non-classical) molecules can be detected on the surface. In the absence of MHC class I, CD8 T cells cannot develop. (CD8 T cells are a subset of T cells involved in the development of acquired immunity.)[citation needed]
Low levels of β2 microglobulin can indicate non-progression of HIV.[citation needed]
Levels of β2 microglobulin can be elevated in multiple myeloma and lymphoma, though in these cases primary amyloidosis (amyloid light chain) and secondary amyloidosis (amyloid associated protein) are more common.[clarification needed] The normal value of β2 microglobulin is <2 mg/L.[5] However, with respect to multiple myeloma, the levels of β2 microglobulin may also be at the other end of the spectrum.[clarification needed] Diagnostic testing for multiple myeloma includes obtaining the β2 microglobulin level, for this level is an important prognostic indicator. As of 2011[update] A patient with a level <4 mg/L is expected to have a median survival of 43 months, while one with a level >4 mg/L has a median survival of only 12 months.[6] β2 microglobulin levels cannot, however, distinguish between monoclonal gammopathy of undetermined significance (MGUS), which has a better prognosis, and smouldering (low grade) myeloma.[7][8]
Loss-of-function mutations in this gene have been reported in cancer patients unresponsive to immunotherapies.[citation needed]
↑Cunningham BA, Wang JL, Berggård I, Peterson PA (November 1973). "The complete amino acid sequence of beta 2-microglobulin". Biochemistry. 12 (24): 4811–22. doi:10.1021/bi00748a001. PMID4586824.
↑Pignone M, Nicoll D; McPhee SJ (2004). Pocket guide to diagnostic tests (4th ed.). New York: McGraw-Hill. p. 191. ISBN0-07-141184-4.
↑Munshi NC, Longo DL, Anderson KC (2011). "Chapter 111: Plasma Cell Disorders". In Loscalzo J, Longo DL, Fauci AS, Dennis LK, Hauser SL. Harrison's Principles of Internal Medicine (18th ed.). McGraw-Hill Professional. pp. 936–44. ISBN0-07-174889-X.
Huang WC, Wu D, Xie Z, Zhau HE, Nomura T, Zayzafoon M, Pohl J, Hsieh CL, Weitzmann MN, Farach-Carson MC, Chung LW (2006). "Beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis". Cancer Res. 66 (18): 9108–16. doi:10.1158/0008-5472.CAN-06-1996. PMID16982753.
Winchester JF, Salsberg JA, Levin NW (2004). "Beta-2 microglobulin in ESRD: an in-depth review". Advances in renal replacement therapy. 10 (4): 279–309. doi:10.1053/j.arrt.2003.11.003. PMID14681859.
Krangel MS, Orr HT, Strominger JL (1980). "Assembly and maturation of HLA-A and HLA-B antigens in vivo". Cell. 18 (4): 979–91. doi:10.1016/0092-8674(79)90210-1. PMID93026.
Okon M, Bray P, Vucelić D (1992). "1H NMR assignments and secondary structure of human beta 2-microglobulin in solution". Biochemistry. 31 (37): 8906–15. doi:10.1021/bi00152a030. PMID1390678.
Guo HC, Jardetzky TS, Garrett TP, et al. (1992). "Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle". Nature. 360 (6402): 364–6. doi:10.1038/360364a0. PMID1448153.
Gattoni-Celli S, Kirsch K, Timpane R, Isselbacher KJ (1992). "Beta 2-microglobulin gene is mutated in a human colon cancer cell line (HCT) deficient in the expression of HLA class I antigens on the cell surface". Cancer Res. 52 (5): 1201–4. PMID1737380.
Saper MA, Bjorkman PJ, Wiley DC (1991). "Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution". J. Mol. Biol. 219 (2): 277–319. doi:10.1016/0022-2836(91)90567-P. PMID2038058.
Caruana RJ, Lobel SA, Leffell MS, et al. (1991). "Tumor necrosis factor, interleukin-1 and beta 2-microglobulin levels in chronic hemodialysis patients". The International journal of artificial organs. 13 (12): 794–8. PMID2289831.
Connors LH, Shirahama T, Skinner M, et al. (1985). "In vitro formation of amyloid fibrils from intact beta 2-microglobulin". Biochem. Biophys. Res. Commun. 131 (3): 1063–8. doi:10.1016/0006-291X(85)90198-6. PMID2413854.
Hochman JH, Shimizu Y, DeMars R, Edidin M (1988). "Specific associations of fluorescent beta-2-microglobulin with cell surfaces. The affinity of different H-2 and HLA antigens for beta-2-microglobulin". J. Immunol. 140 (7): 2322–9. PMID2450918.
Homma N, Gejyo F, Isemura M, Arakawa M (1989). "Collagen-binding affinity of beta-2-microglobulin, a preprotein of hemodialysis-associated amyloidosis". Nephron. 53 (1): 37–40. doi:10.1159/000185699. PMID2674742.
Bataille R, Grenier J, Commes T (1988). "In vitro production of beta 2 microglobulin by human myeloma cells". Cancer Invest. 6 (3): 271–7. doi:10.3109/07357908809080649. PMID3048575.
Hönig R, Marsen T, Schad S, et al. (1989). "Correlation of beta-2-microglobulin concentration changes to changes of distribution volume". The International journal of artificial organs. 11 (6): 459–64. PMID3060434.
Bjorkman PJ, Saper MA, Samraoui B, et al. (1987). "Structure of the human class I histocompatibility antigen, HLA-A2". Nature. 329 (6139): 506–12. doi:10.1038/329506a0. PMID3309677.
Güssow D, Rein R, Ginjaar I, et al. (1987). "The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit". J. Immunol. 139 (9): 3132–8. PMID3312414.
Cunningham BA, Wang JL, Berggård I, Peterson PA (1974). "The complete amino acid sequence of beta 2-microglobulin". Biochemistry. 12 (24): 4811–22. doi:10.1021/bi00748a001. PMID4586824.
Matoba R, Okubo K, Hori N, et al. (1994). "The addition of 5'-coding information to a 3'-directed cDNA library improves analysis of gene expression". Gene. 146 (2): 199–207. doi:10.1016/0378-1119(94)90293-3. PMID8076819.
1akj: COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 AND THE T CELL CORECEPTOR CD8
PDB 1ao7 EBI.jpg
1ao7: COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201
PDB 1b0g EBI.jpg
1b0g: CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A2.1)/BETA 2-MICROGLOBULIN/PEPTIDE P1049 COMPLEX
PDB 1b0r EBI.jpg
1b0r: CRYSTAL STRUCTURE OF HLA-A*0201 COMPLEXED WITH A PEPTIDE WITH THE CARBOXYL-TERMINAL GROUP SUBSTITUTED BY A METHYL GROUP
PDB 1bd2 EBI.jpg
1bd2: COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND MHC CLASS I MOLECULE HLA-A 0201
PDB 1c16 EBI.jpg
1c16: CRYSTAL STRUCTURE ANALYSIS OF THE GAMMA/DELTA T CELL LIGAND T22
PDB 1ce6 EBI.jpg
1ce6: MHC CLASS I H-2DB COMPLEXED WITH A SENDAI VIRUS NUCLEOPROTEIN PEPTIDE
PDB 1cg9 EBI.jpg
1cg9: COMPLEX RECOGNITION OF THE SUPERTYPIC BW6-DETERMINANT ON HLA-B AND-C MOLECULES BY THE MONOCLONAL ANTIBODY SFR8-B6
PDB 1de4 EBI.jpg
1de4: HEMOCHROMATOSIS PROTEIN HFE COMPLEXED WITH TRANSFERRIN RECEPTOR
PDB 1duy EBI.jpg
1duy: CRYSTAL STRUCTURE OF HLA-A*0201/OCTAMERIC TAX PEPTIDE COMPLEX
PDB 1duz EBI.jpg
1duz: HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) IN COMPLEX WITH A NONAMERIC PEPTIDE FROM HTLV-1 TAX PROTEIN
PDB 1e27 EBI.jpg
1e27: NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM1(LPPVVAKEI)
PDB 1e28 EBI.jpg
1e28: NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM2(TAFTIPSI)
PDB 1eey EBI.jpg
1eey: Crystal Structure Determination Of HLA A2 Complexed to Peptide GP2 with the substitution (I2L/V5L/L9V)
PDB 1eez EBI.jpg
1eez: Crystal Structure Determination of HLA-A2.1 Complexed to GP2 Peptide Variant(I2L/V5L)
PDB 1efx EBI.jpg
1efx: STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL RECEPTOR KIR2DL2 AND A CLASS I MHC LIGAND HLA-CW3
PDB 1exu EBI.jpg
1exu: CRYSTAL STRUCTURE OF THE HUMAN MHC-RELATED FC RECEPTOR
PDB 1gzp EBI.jpg
1gzp: CD1B IN COMPLEX WITH GM2 GANGLIOSIDE
PDB 1gzq EBI.jpg
1gzq: CD1B IN COMPLEX WITH PHOPHATIDYLINOSITOL
PDB 1hhg EBI.jpg
1hhg: THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
PDB 1hhh EBI.jpg
1hhh: THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
PDB 1hhi EBI.jpg
1hhi: THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
PDB 1hhj EBI.jpg
1hhj: THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
PDB 1hhk EBI.jpg
1hhk: THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
PDB 1hsa EBI.jpg
1hsa: THE THREE-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROMS RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHC
PDB 1hsb EBI.jpg
1hsb: DIFFERENT LENGTH PEPTIDES BIND TO HLA-AW68 SIMILARLY AT THEIR ENDS BUT BULGE OUT IN THE MIDDLE
PDB 1i1f EBI.jpg
1i1f: CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
PDB 1i1y EBI.jpg
1i1y: CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
PDB 1i4f EBI.jpg
1i4f: CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4-PEPTIDE COMPLEX
PDB 1i7r EBI.jpg
1i7r: CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1058
PDB 1i7t EBI.jpg
1i7t: CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-5V
PDB 1i7u EBI.jpg
1i7u: CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-6V
PDB 1im3 EBI.jpg
1im3: Crystal Structure of the human cytomegalovirus protein US2 bound to the MHC class I molecule HLA-A2/tax
PDB 1im9 EBI.jpg
1im9: Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1 bound to its MHC ligand HLA-Cw4
PDB 1jf1 EBI.jpg
1jf1: Crystal structure of HLA-A2*0201 in complex with a decameric altered peptide ligand from the MART-1/Melan-A
PDB 1jgd EBI.jpg
1jgd: HLA-B*2709 bound to deca-peptide s10R
PDB 1jge EBI.jpg
1jge: HLA-B*2705 bound to nona-peptide m9
PDB 1jht EBI.jpg
1jht: Crystal structure of HLA-A2*0201 in complex with a nonameric altered peptide ligand (ALGIGILTV) from the MART-1/Melan-A.
PDB 1jnj EBI.jpg
1jnj: NMR solution structure of the human beta2-microglobulin
PDB 1k5n EBI.jpg
1k5n: HLA-B*2709 BOUND TO NONA-PEPTIDE M9
PDB 1kpr EBI.jpg
1kpr: The human non-classical major histocompatibility complex molecule HLA-E
PDB 1ktl EBI.jpg
1ktl: The human non-classical major histocompatibility complex molecule HLA-E
PDB 1lds EBI.jpg
1lds: Crystal Structure of monomeric human beta-2-microglobulin
PDB 1lp9 EBI.jpg
1lp9: Xenoreactive complex AHIII 12.2 TCR bound to p1049/HLA-A2.1
PDB 1m05 EBI.jpg
1m05: HLA B8 in complex with an Epstein Barr Virus determinant
PDB 1m6o EBI.jpg
1m6o: Crystal Structure of HLA B*4402 in complex with HLA DPA*0201 peptide
PDB 1mhe EBI.jpg
1mhe: THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
PDB 1mi5 EBI.jpg
1mi5: The crystal structure of LC13 TcR in complex with HLAB8-EBV peptide complex
PDB 1n2r EBI.jpg
1n2r: A natural selected dimorphism in HLA B*44 alters self, peptide reportoire and T cell recognition.
PDB 1of2 EBI.jpg
1of2: CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
PDB 1oga EBI.jpg
1oga: A STRUCTURAL BASIS FOR IMMUNODOMINANT HUMAN T-CELL RECEPTOR RECOGNITION.
PDB 1ogt EBI.jpg
1ogt: CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
PDB 1onq EBI.jpg
1onq: Crystal Structure of CD1a in Complex with a Sulfatide
PDB 1p7q EBI.jpg
1p7q: Crystal Structure of HLA-A2 Bound to LIR-1, a Host and Viral MHC Receptor
PDB 1py4 EBI.jpg
1py4: Beta2 microglobulin mutant H31Y displays hints for amyloid formations
PDB 1q94 EBI.jpg
1q94: Structures of HLA-A*1101 in complex with immunodominant nonamer and decamer HIV-1 epitopes clearly reveal the presence of a middle anchor residue
PDB 1qew EBI.jpg
1qew: HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) COMPLEX WITH A NONAMERIC PEPTIDE FROM MELANOMA-ASSOCIATED ANTIGEN 3 (RESIDUES 271-279)
PDB 1qlf EBI.jpg
1qlf: MHC CLASS I H-2DB COMPLEXED WITH GLYCOPEPTIDE K3G
PDB 1qqd EBI.jpg
1qqd: CRYSTAL STRUCTURE OF HLA-CW4, A LIGAND FOR THE KIR2D NATURAL KILLER CELL INHIBITORY RECEPTOR
PDB 1qr1 EBI.jpg
1qr1: POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTER OF THE PEPTIDE
PDB 1qrn EBI.jpg
1qrn: CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO ALTERED HTLV-1 TAX PEPTIDE P6A
PDB 1qse EBI.jpg
1qse: STRUCTURE OF HUMAN A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE V7R
PDB 1qsf EBI.jpg
1qsf: STRUCTURE OF A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE Y8A
PDB 1qvo EBI.jpg
1qvo: STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THE PRESENCE OF A MIDDLE ANCHOR RESIDUE
PDB 1r3h EBI.jpg
1r3h: Crystal Structure of T10
PDB 1s8d EBI.jpg
1s8d: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-3A
PDB 1s9w EBI.jpg
1s9w: Crystal Structure Analysis of NY-ESO-1 epitope, SLLMWITQC, in complex with HLA-A2
PDB 1s9x EBI.jpg
1s9x: Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQA, in complex with HLA-A2
PDB 1s9y EBI.jpg
1s9y: Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQS, in complex with HLA-A2
PDB 1sys EBI.jpg
1sys: Crystal structure of HLA, B*4403, and peptide EEPTVIKKY
PDB 1syv EBI.jpg
1syv: HLA-B*4405 complexed to the dominant self ligand EEFGRAYGF
PDB 1t1w EBI.jpg
1t1w: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-3F6I8V
PDB 1t1x EBI.jpg
1t1x: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-4L
PDB 1t1y EBI.jpg
1t1y: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-5V
PDB 1t1z EBI.jpg
1t1z: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-6A
PDB 1t20 EBI.jpg
1t20: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-6I
PDB 1t21 EBI.jpg
1t21: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9, monoclinic crystal
PDB 1t22 EBI.jpg
1t22: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9, orthorhombic crystal
PDB 1tmc EBI.jpg
1tmc: THE THREE-DIMENSIONAL STRUCTURE OF A CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE MISSING THE ALPHA3 DOMAIN OF THE HEAVY CHAIN
PDB 1tvb EBI.jpg
1tvb: Crystal structure of Melanoma Antigen gp100(209-217) Bound to Human Class I MHC HLA-A2
PDB 1tvh EBI.jpg
1tvh: Crystal structure of Modified Melanoma Antigen gp100(209-T2M) Bound to Human Class I MHC HLA-A2
PDB 1uqs EBI.jpg
1uqs: THE CRYSTAL STRUCTURE OF HUMAN CD1B WITH A BOUND BACTERIAL GLYCOLIPID
PDB 1uxs EBI.jpg
1uxs: CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2)OF EPSTEIN-BARR VIRUS
PDB 1uxw EBI.jpg
1uxw: CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPSTEIN-BARR VIRUS
PDB 1vgk EBI.jpg
1vgk: The crystal structure of class I Major histocompatibility complex, H-2Kd at 2.0 A resolution
PDB 1w0v EBI.jpg
1w0v: CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1
PDB 1w0w EBI.jpg
1w0w: CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1
PDB 1w72 EBI.jpg
1w72: CRYSTAL STRUCTURE OF HLA-A1:MAGE-A1 IN COMPLEX WITH FAB-HYB3
PDB 1x7q EBI.jpg
1x7q: Crystal structure of HLA-A*1101 with sars nucleocapsid peptide
PDB 1xh3 EBI.jpg
1xh3: Conformational Restraints and Flexibility of 14-Meric Peptides in Complex with HLA-B*3501
PDB 1xr8 EBI.jpg
1xr8: Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus EBNA-3
PDB 1xr9 EBI.jpg
1xr9: Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus EBNA-3
PDB 1xz0 EBI.jpg
1xz0: Crystal structure of CD1a in complex with a synthetic mycobactin lipopeptide
PDB 1ydp EBI.jpg
1ydp: 1.9A crystal structure of HLA-G
PDB 1ypz EBI.jpg
1ypz: Immune receptor
PDB 1zhk EBI.jpg
1zhk: Crystal structure of HLA-B*3501 presenting 13-mer EBV antigen LPEPLPQGQLTAY
PDB 1zhl EBI.jpg
1zhl: Crystal structure of HLA-B*3508 presenting 13-mer EBV antigen LPEPLPQGQLTAY
PDB 1zs8 EBI.jpg
1zs8: Crystal Structure of the Murine MHC Class Ib Molecule M10.5
PDB 1zsd EBI.jpg
1zsd: Crystal Structure Of HLA-B*3501 Presenting an 11-Mer EBV Antigen EPLPQGQLTAY
PDB 1zt4 EBI.jpg
1zt4: The crystal structure of human CD1d with and without alpha-Galactosylceramide
PDB 1zvs EBI.jpg
1zvs: Crystal structure of the first class MHC mamu and Tat-Tl8 complex
PDB 2a83 EBI.jpg
2a83: Crystal structure of hla-b*2705 complexed with the glucagon receptor (gr) peptide (residues 412-420)
PDB 2ak4 EBI.jpg
2ak4: Crystal Structure of SB27 TCR in complex with HLA-B*3508-13mer peptide
PDB 2av1 EBI.jpg
2av1: Crystal structure of HTLV-1 TAX peptide Bound to Human Class I MHC HLA-A2 with the E63Q and K66A mutations in the heavy chain.
PDB 2av7 EBI.jpg
2av7: Crystal structure of HTLV-1 TAX peptide Bound to Human Class I MHC HLA-A2 with the K66A mutation in the heavy chain.
PDB 2axf EBI.jpg
2axf: The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation
PDB 2axg EBI.jpg
2axg: The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation
PDB 2bck EBI.jpg
2bck: Crystal Structure of HLA-A*2402 Complexed with a telomerase peptide
PDB 2bnq EBI.jpg
2bnq: STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES
PDB 2bnr EBI.jpg
2bnr: STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES
PDB 2bsr EBI.jpg
2bsr: CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
PDB 2bss EBI.jpg
2bss: CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
PDB 2bst EBI.jpg
2bst: CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
PDB 2bsu EBI.jpg
2bsu:
PDB 2bsv EBI.jpg
2bsv:
PDB 2bvo EBI.jpg
2bvo: STRUCTURES OF THREE HIV-1 HLA-B5703-PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG-TERM NON-PROGRESSION
PDB 2bvp EBI.jpg
2bvp: STRUCTURES OF THREE HIV-1 HLA-B5703-PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG-TERM NON-PROGRESSION
PDB 2bvq EBI.jpg
2bvq: STRUCTURES OF THREE HIV-1 HLA-B5703-PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG-TERM NON-PROGRESSION
PDB 2c7u EBI.jpg
2c7u: CONFLICTING SELECTIVE FORCES AFFECT CD8 T-CELL RECEPTOR CONTACT SITES IN AN HLA-A2 IMMUNODOMINANT HIV EPITOPE.
PDB 2cii EBI.jpg
2cii: THE CRYSTAL STRUCTURE OF H-2DB COMPLEXED WITH A PARTIAL PEPTIDE EPITOPE SUGGESTS AN MHC CLASS I ASSEMBLY-INTERMEDIATE
PDB 2cik EBI.jpg
2cik: INSIGHTS INTO CROSSREACTIVITY IN HUMAN ALLORECOGNITION: THE STRUCTURE OF HLA-B35011 PRESENTING AN EPITOPE DERIVED FROM CYTOCHROME P450.
PDB 2clr EBI.jpg
2clr: THREE DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING OUT ONE END OF A CLASS I MHC BINDING SITE
PDB 2d31 EBI.jpg
2d31: Crystal structure of disulfide-linked HLA-G dimer
PDB 2d4d EBI.png
2d4d: The Crystal Structure of human beta2-microglobulin, L39W W60F W95F Mutant
PDB 2d4f EBI.jpg
2d4f: The Crystal Structure of human beta2-microglobulin
PDB 2dyp EBI.jpg
2dyp: Crystal Structure of LILRB2(LIR2/ILT4/CD85d) complexed with HLA-G
PDB 2esv EBI.jpg
2esv: Structure of the HLA-E-VMAPRTLIL/KK50.4 TCR complex
PDB 2f53 EBI.jpg
2f53: Directed Evolution of Human T-cell Receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without apparent cross-reactivity
PDB 2f54 EBI.jpg
2f54: Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity
PDB 2f74 EBI.jpg
2f74: Murine MHC class I H-2Db in complex with human b2-microglobulin and LCMV-derived immunodminant peptide gp33
PDB 2f8o EBI.png
2f8o: A Native to Amyloidogenic Transition Regulated by a Backbone Trigger
PDB 2fyy EBI.jpg
2fyy: The role of T cell receptor alpha genes in directing human MHC restriction
PDB 2fz3 EBI.jpg
2fz3: The role of T cell receptor alpha genes in directing human MHC restriction
PDB 2git EBI.jpg
2git: Human Class I MHC HLA-A2 in complex with the modified HTLV-1 TAX (Y5K-4-[3-Indolyl]-butyric acid) peptide
PDB 2gj6 EBI.jpg
2gj6: The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5K-4-[3-Indolyl]-butyric acid) peptide
PDB 2h26 EBI.jpg
2h26: human CD1b in complex with endogenous phosphatidylcholine and spacer
PDB 2h6p EBI.jpg
2h6p: Crystal structure of HLA-B*3501 presenting the human cytochrome P450 derived peptide, KPIVVLHGY
PDB 2hjk EBI.jpg
2hjk: Crystal Structure of HLA-B5703 and HIV-1 peptide
PDB 2hjl EBI.jpg
2hjl: Crystal Structure of HLA-B5703 and HIV-1 peptide
PDB 2hla EBI.jpg
2hla: SPECIFICITY POCKETS FOR THE SIDE CHAINS OF PEPTIDE ANTIGENS IN HLA-AW68
PDB 2hn7 EBI.jpg
2hn7: HLA-A*1101 in complex with HBV peptide homologue
PDB 2nw3 EBI.jpg
2nw3: Crystal structure of HLA-B*3508 presenting EBV peptide EPLPQGQLTAY at 1.7A
PDB 2nx5 EBI.jpg
2nx5: Crystal structure of ELS4 TCR bound to HLA-B*3508 presenting EBV peptide EPLPQGQLTAY at 1.7A
PDB 3hla EBI.jpg
3hla: HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2.1
